Is Big Pharma too Big to Meet the Needs of Patients?

When does big pharma become so big that it becomes ineffective? In what is now a rapidly changing industry, some business leaders believe that pharma needs to be more nimble and flexible.

Kirsten O’Doherty, General Manager, AbbVie Australia & New Zealand and Geoff Blundell, Marketing Director, A. Menarini Australia, spoke with eyeforpharma  on the differences between successful business model. 
 
O’Doherty explained the driving factors behind the decision to separate and formally launch a new company Abbvie, in order to create companies that led to: “proven legacies, renewed focus and robust plans to improve people’s health.”
 
Blundell believes there are many different business models, emphasising that he thinks there really is no best fit model, rather different paradigms to suit different situations.
 
Acting as a small-scale business can really drives results. O’Doherty highlighted the important of this for eyeforpharma in their article “Why Pharma Should Think Big And Act Small: “the ability to be nimble, flexible and focused on delivering superior benefits to patients – are all critical to success.”
 
Geoff Blundell will be moderating a panel  focussing on “Seize the opportunity for creative disruption around commercial models“ at the Sales & Marketing Excellence Australia Summit, 8-9 October in Sydney, find out more at the official website
 
###.
 
About eyeforpharma:
 
eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay up to date with shifting trends and practices within the pharmaceutical industry. We provide industry-focused commentary, events, reports, and other valuable expert-driven content. Our ultimate aim is to facilitate positive change through discussion and debate, enabling dialogue within the industry and driving the positive benefits that pharmaceuticals can offer.
Contact:
 
Lucy Fisher
VP Europe & Asia Pacific | eyeforpharma
T: +44 (0) 207 375 7225 
 
###
 
comments powered by Disqus